Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing dendritic cell-based immunotherapy for cancer.

Hua Zhong1, Michael R Shurin, Baohui Han

  • 1Shanghai Jiao Tong University, Shanghai Chest Hospital, 241 Huaihai Road (w), Shanghai 200030, China. harriet_zhong@hotmail.com

Expert Review of Vaccines
|June 5, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DAZAP2, regulated by miR-125b, contributes to inflammation-related non-small cell lung cancer progression.

Translational oncology·2026
Same author

Development and internal validation of dynamic nomograms for predicting recurrence and survival in patients with resected combined small cell lung cancer.

Journal of thoracic disease·2026
Same author

Efficacy and safety of first-line oral vinorelbine plus firmonertinib in refractory <i>EGFR</i>-mutated non-small cell lung cancer: study protocol of a multicenter, non-randomized, two-cohort study.

Therapeutic advances in medical oncology·2026
Same author

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Nature communications·2026
Same author

International Consensus on Severe Lung Cancer-The Second Edition.

Translational lung cancer research·2026
Same author

GLUT6-facilitated noncanonical glucose metabolic rewiring enables resistance to targeted cancer therapy.

Nature communications·2026

Dendritic cell (DC) vaccines show promise for cancer therapy by initiating antitumor immune responses. However, challenges in DC preparation and vaccination protocols hinder definitive conclusions on clinical efficacy.

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • Dendritic cells (DCs) are potent antigen-presenting cells crucial for initiating and regulating immune responses, including antitumor immunity.
  • Practical methods for generating functional human DCs from peripheral blood have enabled clinical trials for cancer treatment.

Purpose of the Study:

  • To review the current status and challenges in the development of dendritic cell (DC)-based cancer vaccines.
  • To identify key unanswered questions impacting the clinical and immunological efficacy of DC vaccination.

Main Methods:

  • Literature review of clinical trials and research on dendritic cell vaccination in cancer patients.
  • Analysis of critical factors in DC vaccine development, including preparation, antigen loading, administration, and monitoring.

Related Experiment Videos

Main Results:

  • Despite 12 years of clinical trials, definitive conclusions on the efficacy of DC vaccination remain elusive.
  • Numerous challenges persist, including optimal DC source, generation protocols, antigen selection, administration routes, and immunomonitoring.

Conclusions:

  • Dendritic cell vaccines continue to hold promise for cancer therapy.
  • Further research is needed to address existing challenges and optimize DC-based immunotherapy strategies.